Newsmeme!
Discover News you didn't know existed
Ribose
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
BioMarin to Expand, Offers Guidance
Published February 9, 2010, 8:13 am, Zacks.com via Yahoo! Finance
BioMarin expects net income between $39 million to $49 million in 2010.
Alnylam Receives Notice of Allowance for US Patent Application on RNAi Agents
Published February 8, 2010, 1:30 pm, GenomeWeb News
Alnylam Pharmaceuticals said this week that the US Patent and Trademark Office has issued a notice of allowance for a company patent application covering "certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates, for in vivo delivery."
Alnylam Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Broadly Covering ...
Published February 8, 2010, 5:00 am, Business Wire via Yahoo! Finance
CAMBRIDGE, Mass.----Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office has awarded a Notice of Allowance for the “Soutschek and Manoharan” patent , which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery.
BioMarin to acquire private drug discovery firm LEAD Therapeutics
Published February 5, 2010, 11:36 pm, PharmaBiz
BioMarin Pharmaceutical Inc. announced that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.
Carping Over PARPs: Buyout Equals 'Negative' for BioMarin?
Published February 5, 2010, 5:35 pm, BioWorld
With promising early data and a clear Phase III pathway for its GALNS drug in a rare lysosomal storage disorder, BioMarin Pharmaceuticals Inc. said it is no longer in critical need of late-stage assets to fill out its pipeline.
The Fountain of Youth
Published February 5, 2010, 12:38 pm, Beverage World
Beverages that provide bone, joint and heart health ingredients are targeting the increasingly active Baby Boomer generation.
BioMarin Pharmaceutical signs stock purchase agreement to acquire LEAD Therapeutics
Published February 4, 2010, 8:31 pm, News-Medical-Net
BioMarin Pharmaceutical Inc. announced today that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |